Research location
Rosenheim
Bavaria, Germany
Advertisement
Research activity in Rosenheim
Bavaria, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 19 trials and 19 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Rosenheim
19 linked trials · page 1 of 1A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 · 2024-04-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)NCT03345407 · 2017-11-28 · 1 site observation
TERMINATED
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With AsthmaNCT03248128 · 2017-10-20 · 1 site observation
COMPLETED
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02164513 · 2014-06-30 · 1 site observation
COMPLETED
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in ChildrenNCT01573767 · 2012-04-01 · 1 site observation
COMPLETED
A Dose-ranging Study of Fluticasone Furoate (FF)NCT01563029 · 2012-03-28 · 1 site observation
COMPLETED
Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD PatientsNCT02007772 · 2011-06-01 · 1 site observation
COMPLETED
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast CancerNCT00820222 · 2009-04-14 · 1 site observation
COMPLETED
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast CancerNCT00667251 · 2008-10-07 · 1 site observation
COMPLETED
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast CancerNCT00558103 · 2007-12-01 · 1 site observation
COMPLETED
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung CancerNCT00480025 · 2007-10-04 · 1 site observation
TERMINATED
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast CancerNCT00374322 · 2006-08-01 · 1 site observation
COMPLETED
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant ChemotherapyNCT00512993 · 2004-12-01 · 1 site observation
COMPLETED
Viapaed Study In Children And Adolescents With AsthmaNCT00315744 · 2004-11-04 · 1 site observation
COMPLETED
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast CancerNCT00073528 · 2003-12-09 · 1 site observation
COMPLETED
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskNCT00056407 · 2003-03-01 · 1 site observation
COMPLETED
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung CancerNCT00320359 · 2002-08-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.